Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Conditions: Head and Neck Cancer Interventions: Radiation: radical radiotherapy (60Gy); Radiation: radical radiotherapy (66Gy); Radiation: radical radiotherapy (70Gy); Combination Product: anti-PD-1 or PD-L1 antibody Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials